Jungbluth Achim A, Chen Yao-Tseng, Busam Klaus J, Coplan Keren, Kolb Denise, Iversen Kristin, Williamson Barbara, Van Landeghem Frank K H, Stockert Elisabeth, Old Lloyd J
Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Int J Cancer. 2002 Jun 20;99(6):839-45. doi: 10.1002/ijc.10416.
CT7 (MAGE-C1) is a member of the cancer testis (CT) antigen family. The present study describes the generation of CT7-33, a monoclonal antibody (MAb) to CT7, and the preliminary protein expression analysis of CT7 in normal tissues and in a limited number of neoplastic lesions. CT7-33 was effective in frozen as well as formalin-fixed, paraffin-embedded tissues, and immunohistochemistry/reverse transcriptase polymerase chain reaction (RT-PCR) co-typing demonstrated antibody specificity. CT7-33 immunoreactivity in normal adult tissues is restricted to testicular germ cells. In neoplastic lesions, CT7-33 immunostaining is confined to tumor cells, and the frequency of CT7 protein expression mostly parallels previous mRNA analyses. Whereas colorectal and renal cell carcinomas, as well as sarcomas, exhibit poor or no CT7-33 staining, carcinomas of the mammary gland and ovary, nonsmall cell lung carcinoma and metastatic melanomas exhibit a high incidence of CT7 protein expression. However, as seen in previous analyses of other CT antigens, the expression pattern is mostly heterogeneous, and tumors with more than 50% of tumor staining are only infrequently encountered. In summary, our study presents a new serologic reagent for the analysis of CT7 on a protein level and confirms what is known with regard to the expression pattern of other CT antigens in tumors: frequent heterogeneity of antigen expression.
CT7(MAGE-C1)是癌睾丸(CT)抗原家族的一员。本研究描述了CT7-33的产生,CT7-33是一种针对CT7的单克隆抗体(MAb),并对CT7在正常组织和有限数量的肿瘤病变中的蛋白质表达进行了初步分析。CT7-33在冰冻组织以及福尔马林固定、石蜡包埋的组织中均有效,免疫组织化学/逆转录聚合酶链反应(RT-PCR)共同分型证明了抗体的特异性。CT7-33在正常成人组织中的免疫反应性仅限于睾丸生殖细胞。在肿瘤病变中,CT7-33免疫染色局限于肿瘤细胞,CT7蛋白表达频率大多与先前的mRNA分析结果一致。结直肠癌和肾细胞癌以及肉瘤的CT7-33染色较差或无染色,而乳腺癌、卵巢癌、非小细胞肺癌和转移性黑色素瘤的CT7蛋白表达发生率较高。然而,正如先前对其他CT抗原的分析所见,表达模式大多是异质性的,肿瘤染色超过50%的情况很少见。总之,我们的研究提供了一种新的血清学试剂,用于在蛋白质水平上分析CT7,并证实了关于肿瘤中其他CT抗原表达模式的已知情况:抗原表达频繁异质性。